Carsten Niemann, MD, PhD

Articles

Reflections and Future Directions in CLL Management

February 17th 2025

Panelists comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates.

Emerging Agents and Future Strategies in Relapsed/Refractory CLL

February 17th 2025

Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).

Progression on BTK Inhibitors: Treatment Options and Considerations

February 10th 2025

Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.

Relapse After Venetoclax-Based Therapy: Early vs Late Management

February 10th 2025

Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.

Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy

February 3rd 2025

Panelists discuss the ongoing trials evaluating other BCL2i/BTKi combination approaches.

Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies

February 3rd 2025

Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation.

Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

January 27th 2025

Panelists discuss the role of ven-ibr in patient populations.

Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

January 27th 2025

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

Clinical Insights and Real-World Evidence

January 24th 2025

Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.

Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data

January 24th 2025

Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.

Dr Niemann on the Investigation of Ibrutinib Plus Ventoclax in CLL

January 21st 2025

Carsten Niemann, MD, PhD, discusses long-term follow-up data from the phase 3 GLOW trial evaluating fixed-duration ibrutinib plus venetoclax in CLL.

Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients

January 15th 2025

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

January 8th 2025

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

Recent Guideline Updates in the Frontline Management of CLL

January 6th 2025

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

Dr. Niemann on Notable Findings from the GLOW Trial in CLL

January 6th 2023

Carsten Niemann, MD, PhD, discusses notable data on patient survival outcomes, as well as the impact of minimal residual disease in the peripheral blood from the phase 3 GLOW trial in patients with chronic lymphocytic leukemia.

Dr. Niemann on Ibrutinib Plus Venetoclax Vs Chlorambucil and Obinutuzumab in Mutated CLL

December 19th 2022

Carsten Niemann, MD, PhD, discusses ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in mutated chronic lymphocytic leukemia.